Cap Biosciences: Delay of one year in the development of anti-HPV and nucleic acid diagnostic projects.

Cap Biotechnology announced that on March 18th, the company held a board meeting and agreed to extend the expected date for the completion of the research and development projects for anti-HPV drugs and nucleic acid molecular diagnostic products to be in a usable state by one year to March 2027. The implementation content and total investment amount remain unchanged. As of December 31, 2025, a total of 50.5934 million yuan and 244.0668 million yuan have been invested in the two projects respectively, with the extension being due to longer research and testing periods and adjustments in development strategies. This matter does not require shareholder approval, and all parties have expressed their agreement.